Clinical Trial

Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae

Study acronym: LAMBEAU STEPA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 15, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase 1b, multicenter, non-randomized prospective study involving an innovation phase (IDEAL-1) followed by a prospective development phase (IDEAL-2A) designed to evaluate the safety and feasibility of oral/oropharyngeal reconstruction with the external pudendal free flap in two groups of patients. A maximum of 40 patients (20 patients per group) will be included in this IDEAL-1/2A phase study. Stage IDEAL-1: Innovation phase. The main objective is to evaluate the feasibility in terms of limiting surgical complications of a STEPA flap reconstruction in two groups of patients (Cohort: Male, Female). Stage IDEAL-2A: Prospective development phase. The main objective is to describe the complication profile of the surgical procedure in these two patient populations. Each patient will be followed during 12 months after the end of complete treatment (surgery ± adjuvant treatment). A complementary study (observational study) of 250 patients will also be conducted to evaluate the acceptability of the technique (reconstruction by external pudendal flap) by the patients and to describe the factors associated with this acceptability.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-02-24; most recent amendment 2025-09-11.
Status change: Not Yet Recruiting → Recruiting 2023-08-09
Trial Details
NCT Number NCT05757817
Lead Sponsor Institut Claudius Regaud
Conditions Head and Neck Cancer, Oral Cavity Cancer, Oropharynx Cancer
Enrollment 40 participants
Start Date 2023-11-08
Primary Completion 2026-05 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-15